Findings

What do systematic reviews say?

84 questions · 97 findings · 11 reviews · Infectious Diseases · Headline outcomes only

Sort:Best matchNewest Highest certainty Download CSV

No studies found 6 · 6.2%GRADE not reported 7 · 7.2%Very low 20 · 20.6%Low 28 · 28.9%Moderate 22 · 22.7%High 14 · 14.4%

Oral iron vs placebo or no treatment

Subgroup · children in malaria‐endemic areas

The review found no eligible studies for this question.

1 finding from 1 review

Oral iron supplements for children in malaria‐endemic areas 2016 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Oral iron vs placebo or no treatment

Clinical malaria · children in malaria‐endemic areas

Oral iron showed no clear difference in clinical malaria compared with placebo or no treatment (high certainty).

1 finding from 1 review

Oral iron supplements for children in malaria‐endemic areas 2016 · Cochrane Headline outcomes only
RR 0.93 [0.87, 1]
14 studies · 7168 participants
High

Oral iron vs placebo or no treatment

Clinical malaria Subgrouped by population anaemia (trial level) · children in malaria‐endemic areas

Oral iron showed no clear difference in clinical malaria Subgrouped by population anaemia (trial level) compared with placebo or no treatment (moderate certainty).

1 finding from 1 review

Oral iron supplements for children in malaria‐endemic areas 2016 · Cochrane Headline outcomes only
RR 0.92 [0.84, 1]
14 studies · 7168 participants
Moderate

Oral iron vs placebo or no treatment

Severe malaria · children in malaria‐endemic areas

Oral iron leads to lower severe malaria Defined as clinical malaria with high‐grade… compared with placebo or no treatment (high certainty).

1 finding from 1 review

Oral iron supplements for children in malaria‐endemic areas 2016 · Cochrane Headline outcomes only
RR 0.9 [0.81, 0.98]
6 studies · 3421 participants
High

Oral iron vs placebo or no treatment

Death · children in malaria‐endemic areas

1 finding from 1 review

Oral iron supplements for children in malaria‐endemic areas 2016 · Cochrane Headline outcomes only
no estimate extracted
18 studies · 7576 participants
Low

Oral iron vs placebo or no treatment

Hospitalization plus clinic visits · children in malaria‐endemic areas

It is very uncertain whether oral iron changes hospitalization plus clinic visits compared with placebo or no treatment (very low certainty).

1 finding from 1 review

Oral iron supplements for children in malaria‐endemic areas 2016 · Cochrane Headline outcomes only
RR 0.99 [0.95, 1.04]
6 studies · 12578 participants
Very low

Oral ivermectin 200 μg/kg (1 dose) vs oral ivermectin 200 μg/kg (2 doses)

Complete clearance · people with scabies, over 5 years of ageLocation: India

Oral ivermectin 200 μg/kg (1 dose) showed no clear difference in complete clearance ‐ week 4 compared with oral ivermectin 200 μg/kg (2 doses) (high certainty).

1 finding from 1 review

Ivermectin and permethrin for treating scabies 2018 · Cochrane Headline outcomes only
RR 0.97 [0.83, 1.14]
1 study · 80 participants
High

Oral ivermectin 200 μg/kg (1 dose) vs oral ivermectin 200 μg/kg (2 doses)

1Sharma 2011. · people with scabies, over 5 years of ageLocation: India

1 finding from 1 review

Ivermectin and permethrin for treating scabies 2018 · Cochrane Headline outcomes only
no estimate extracted
1 participants
GRADE not reported

Oral iron with antimalarial prophylaxis vs placebo or no treatment

All‐cause mortality · children with or without anaemia at baseline

Oral iron with antimalarial prophylaxis showed no clear difference in all‐cause mortality compared with placebo or no treatment (low certainty).

1 finding from 1 review

Oral iron supplements for children in malaria‐endemic areas 2016 · Cochrane Headline outcomes only
RR 1.05 [0.52, 2.11]
728 participants
Low

Oral iron with antimalarial prophylaxis vs placebo or no treatment

Clinical malaria · children with or without anaemia at baseline

Oral iron with antimalarial prophylaxis leads to lower clinical malaria compared with placebo or no treatment (high certainty).

1 finding from 1 review

Oral iron supplements for children in malaria‐endemic areas 2016 · Cochrane Headline outcomes only
RR 0.54 [0.43, 0.67]
728 participants
High

WC‐rBS vaccine (Dukoral): two doses ± booster dose vs placebo

Cases of cholera ( · healthy children and adults; high risk population

1 finding from 1 review

Oral killed cholera vaccines for preventing cholera 2024 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 16423 participants
High

Oral gentamicin vs nalidixic acid

Diarrhoea · patients with Shigella dysentery

It is very uncertain whether oral gentamicin changes diarrhoea at compared with nalidixic acid (very low certainty).

1 finding from 1 review

Antibiotic therapy for Shigella dysentery 2010 · Cochrane Headline outcomes only
RR 1.71 [0.98, 2.97]
1 study · 79 participants
Very low

Oral gentamicin vs nalidixic acid

Relapse ‐ not reported · patients with Shigella dysentery

The review found no eligible studies for this question.

1 finding from 1 review

Antibiotic therapy for Shigella dysentery 2010 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Oral gentamicin vs nalidixic acid

Serious adverse events ‐ not reported · patients with Shigella dysentery

The review found no eligible studies for this question.

1 finding from 1 review

Antibiotic therapy for Shigella dysentery 2010 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Oral gentamicin vs nalidixic acid

Other adverse events ‐ not reported · patients with Shigella dysentery

The review found no eligible studies for this question.

1 finding from 1 review

Antibiotic therapy for Shigella dysentery 2010 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Oral erythromycin vs placebo or no intervention

Clinical failure clinical observation · patients with BCG adverse reactions1

It is very uncertain whether oral erythromycin changes clinical failure clinical observation compared with placebo or no intervention (very low certainty).

1 finding from 1 review

Treating BCG‐induced disease in children 2013 · Cochrane Headline outcomes only
RR 1.03 [0.7, 1.53]
3 studies · 148 participants
Very low

Oral Isoniazid (INH) vs no intervention

Clinical failure clinical observation · patients with BCG adverse reactions1

It is very uncertain whether oral Isoniazid (INH) changes clinical failure clinical observation compared with no intervention (very low certainty).

1 finding from 1 review

Treating BCG‐induced disease in children 2013 · Cochrane Headline outcomes only
RR 1.48 [0.79, 2.78]
2 studies · 54 participants
Very low

Oral isoniazid plus rifampicin vs no intervention

Clinical failure clinical observation · infants with BCG vaccine adverse reactions1

It is very uncertain whether oral isoniazid plus rifampicin changes clinical failure clinical observation compared with no intervention (very low certainty).

1 finding from 1 review

Treating BCG‐induced disease in children 2013 · Cochrane Headline outcomes only
RR 1.2 [0.51, 2.83]
1 study · 35 participants
Very low

Oral ivermectin 200 μg/kg (1 to 3 doses) vs topical permethrin 5% cream (1 to 3 applications)

Complete clearance · people with scabies, 2 to 80 years of ageLocation: India, Pakistan

Oral ivermectin 200 μg/kg (1 to 3 doses) may leads to lower complete clearance ‐ week 1 compared with topical permethrin 5% cream (1 to 3 applications) (low certainty).

5 findings from 1 review

Ivermectin and permethrin for treating scabies 2018 · Cochrane Headline outcomes only
RR 0.65 [0.54, 0.78]
6 studies · 613 participants
Low
Ivermectin and permethrin for treating scabies 2018 · Cochrane Headline outcomes only
RR 0.91 [0.76, 1.08]
5 studies · 459 participants
Low
Ivermectin and permethrin for treating scabies 2018 · Cochrane Headline outcomes only
RR 1 [0.86, 1.16]
1 study · 80 participants
High

Show 2 more findings

Ivermectin and permethrin for treating scabies 2018 · Cochrane Headline outcomes only
RR 0.92 [0.82, 1.03]
5 studies · 581 participants
Low
Ivermectin and permethrin for treating scabies 2018 · Cochrane Headline outcomes only
RR 0.97 [0.83, 1.14]
1 study · 80 participants
High

Oral ivermectin 200 μg/kg (1 to 2 doses) vs topical permethrin 5% lotion (1 to 5 applications)

Complete clearance · people with scabies, 5 to 60 years of ageLocation: Egypt, Pakistan

Oral ivermectin 200 μg/kg (1 to 2 doses) showed no clear difference in complete clearance ‐ week 1 ‐ IVER 1 dose versus PER on 5… compared with topical permethrin 5% lotion (1 to 5 applications) (low certainty).

4 findings from 1 review

Ivermectin and permethrin for treating scabies 2018 · Cochrane Headline outcomes only
RR 0.7 [0.47, 1.03]
1 study · 107 participants
Low
Ivermectin and permethrin for treating scabies 2018 · Cochrane Headline outcomes only
RR 1 [0.78, 1.29]
1 study · 120 participants
Low
Ivermectin and permethrin for treating scabies 2018 · Cochrane Headline outcomes only
RR 0.97 [0.81, 1.17]
1 study · 107 participants
Moderate

Show 1 more finding

Ivermectin and permethrin for treating scabies 2018 · Cochrane Headline outcomes only
RR 0.93 [0.74, 1.17]
1 study · 120 participants
Moderate